MOR - MorphoSys AG

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.15
+0.49 (+1.99%)
As of 3:17PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close24.66
Open24.80
Bid25.08 x 1400
Ask25.19 x 800
Day's Range24.78 - 25.17
52 Week Range21.75 - 35.90
Volume24,234
Avg. Volume67,823
Market Cap3.165B
Beta (3Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MorphoSys AG (MOR) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    MorphoSys AG (MOR) Q1 2019 Earnings Call Transcript

    MOR earnings call for the period ending March 31, 2019.

  • ACCESSWIRElast month

    MorphoSys AG to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / MorphoSys AG (NASDAQ: MOR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 2:00 PM Eastern Time. To ...

  • ACCESSWIRElast month

    MorphoSys AG Reports First Quarter 2019 Results

    Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. ...

  • ACCESSWIRE2 months ago

    MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma

    NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. "The initiation of our first phase 3 trial represents another important milestone in advancing MOR202/TJ202 towards registration with the hope of providing more therapeutic options for multiple myeloma patients globally. Under I-Mab's fast-to-market development strategy, the phase 3 study, if successful, could lead to a biologics license application (BLA) in Greater China.

  • Here’s What Hedge Funds Think About MorphoSys AG (MOR)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About MorphoSys AG (MOR)

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • ACCESSWIRE2 months ago

    MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients

    PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / April 23, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR), Galapagos NV (Euronext & NASDAQ: GLPG) and Novartis Pharma ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • ACCESSWIRE2 months ago

    MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 15, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC ...

  • ACCESSWIRE3 months ago

    Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations

    Sarah joins MorphoSys from Qiagen N.V., a leading global provider of sample and assay technologies for molecular diagnostics, academic research, the pharmaceutical industry and applied testing. Qiagen is listed in the German indexes MDAX and TecDAX as well as at the New York Stock Exchange. Sarah has held the position of Director Investor Relations since April 2018 at Qiagen N.V. in Hilden.

  • ACCESSWIRE3 months ago

    MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

    NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 2 clinical study in Taiwan to evaluate MorphoSys's investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma.

  • ACCESSWIRE3 months ago

    MorphoSys Presents Results for Fiscal Year 2018

    Conference call and webcast (in English) tomorrow, March 14, 2019 at 2:00pm CET (1:00pm GMT/9:00am EDT) Highlights in R&D and corporate development - Interim data from all patients enrolled in ongoing ...

  • ACCESSWIRE3 months ago

    MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL

    Nasdaq: MOR) today provided updates on L-MIND and B-MIND, its two ongoing clinical trials of the investigational Fc-enhanced anti-CD19 antibody MOR208 in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. The Company intends to use L-MIND as the basis for a regulatory filing to the FDA, which it expects to complete by the end of this year. In parallel, the Company has initiated discussions with National European Regulatory Authorities to explore the possibility of using the L-MIND study as the basis for the submission of a potential marketing authorization application (MAA) in Europe.

  • ACCESSWIRE3 months ago

    Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 4, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq: MOR) will publish its Annual Financial Results 2018 on March 13, 2019 at 10:00pm ...

  • ACCESSWIRE4 months ago

    MorphoSys to Present at Upcoming Investor Conference

    PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 21, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference: 8th Annual Leerink Partners ...

  • ACCESSWIRE4 months ago

    Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

    NASDAQ: MOR), informed the Company's Supervisory Board today that he has decided not to renew his contract as a member of the company's Management Board. As a result of his decision, Dr. Moroney will step down as CEO on expiry of his current contract on June 30, 2020, or when a successor is appointed, whichever comes sooner. Dr. Moroney co-founded MorphoSys in 1992, becoming Chief Executive Officer in 1994, a position that he has filled until the present time.

  • ACCESSWIRE4 months ago

    Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire

    NASDAQ: MOR), informed the Company's Supervisory Board today that he has decided not to renew his contract as a member of the company's Management Board. As a result of his decision, Dr. Moroney will step down as CEO on expiry of his current contract on June 30, 2020, or when a successor is appointed, whichever comes sooner. In accepting Dr. Moroney's decision, Dr. Marc Cluzel, Chairman of the Supervisory Board of MorphoSys said, "On behalf of the entire Supervisory Board, I want to extend my deep appreciation to Simon for his extraordinary vision and leadership over the past 27 years.

  • ACCESSWIRE5 months ago

    MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab

    NASDAQ: MOR) announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute. On April 4, 2016 MorphoSys had filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. MorphoSys had sought redress for alleged infringement by Janssen's and Genmab's daratumumab, a CD38-directed monoclonal antibody for the treatment of multiple myeloma.

  • ACCESSWIRE5 months ago

    MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab

    The Court thus granted a motion for Summary Judgement of invalidity filed by Janssen Biotech and Genmab, A/S against the three patents held by MorphoSys. As a result of this decision, the jury trial scheduled for February 2019 to consider defendants' alleged infringement and the validity of the MorphoSys patents will now not take place.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...

  • ACCESSWIRE5 months ago

    MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis

    NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen), has further expanded the clinical development of guselkumab (Tremfya(R)) into ulcerative colitis (UC). Janssen has initiated a proof-of-concept phase 2a clinical trial in patients with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease.

  • ACCESSWIRE6 months ago

    MorphoSys AG: Corporate Calendar 2019

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 17, 2018 / MorphoSys (FSE: MOR; NASDAQ: MOR) Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2019 as follows: Publication of Interim Statement ...

  • ACCESSWIRE6 months ago

    MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis

    NASDAQ: MOR) announced today that according to the title of a presentation to be held next Wednesday afternoon CET (December 12, 2018) at the upcoming Inflammatory Skin Disease Summit (ISDS) conference in Vienna, Austria, guselkumab [Tremfya(R)] demonstrates superior long-term responses to secukinumab [Cosentyx(R)] at Week 48 in the treatment of moderate to severe psoriasis, as results from the ECLIPSE trial. The presentation title has been published online at the website of the ISDS conference (http://www.isds2018.org/scientific-program). MorphoSys expects that this announcement relates to an upcoming presentation of clinical data from the so called "ECLIPSE" clinical study.

  • ACCESSWIRE7 months ago

    MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018

    PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today presented data from the ongoing single-arm phase 2 clinical trial ...